Outlook Therapeutics Provides Update on Type A Meeting with FDA
(NASDAQ:OTLK),(NASDAQ:OTLKW), ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has completed the Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response […]